seeking biotech alpha - 2018 intel

Labiotech.eu - The-Basel-Area-Biotech & Pharma Ecosystem

 It takes an ecosystem to build a startup and world class innovation to build a good biotech company. And to develop a scientific discovery into a life-changing drug or technology, it takes experts from various fields. All of this and more can be found nestled between the borders of France and Germany, namely, in the Basel Area in Switzerland. 

Labiotech.eu

 Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories! . 

 "We are building the Next Generation of Digital Media for Biotech"

Philip, Joachim and the growing team at Labiotech.eu

Infographic: The Basel Area Biotech & Pharma Ecosystem

©2018 MarketsandMarkets Research Private Ltd.

Biomarker Technologies Market

 Biomarker Technologies Market by Profiling Technology (Chromatography, NGS, PCR, Mass Spectrometry, Immunoassay, Liquid Biopsy (ddPCR, DHPLC)), Research Area (Proteomics, Lipidomics), Application (Biomarker Validation, Biomarker Discovery) - Global Forecast to 2022

The global biomarker technologies market is expected to reach USD 74.51 Billion in 2022 from USD 42.88 Billion in 2016, at a CAGR of 9.7% during the forecast period. The base year considered for the study is 2016 and the forecast period is from 2017 to 2022.

Efficacy Testing Market

 Efficacy Testing Market by Product and Service (Consumables, Services), Type (Antimicrobial Efficacy Testing, Disinfectant Efficacy Testing), Application (Pharmaceutical Manufacturing, Cosmetic & Personal Care Products) - Global Forecast to 2022

The efficacy testing market was valued at USD 304.2 Million in 2016 and is expected to reach USD 501.6 Million by 2022, at a CAGR of 8.7%. The base year for this study is 2016 and the forecast period is 2017–2022.

Oncology Information System Market

 Oncology Information System Market by Software (Patient Information System & TPS), & Professional Service), Application (Medical, Radiation, & Surgical Oncology), End User (Hospital, Government Institution, & Research Center) - Global Forecasts to 2019

The market is expected to reach $2.6 billion by 2019 at a CAGR of 8.5% from 2014 to 2019.

Non Invasive Prenatal Testing (NIPT) Market

 Non Invasive Prenatal Testing (NIPT) Market by Instruments (Ultrasound, NGS, PCR, Microarray), Consumables, Method (FCMB, cf-DNA), Application (Trisomy, Microdeletion, Genetics, Rh factor) & End User (Hospital, Diagnostic Labs) - Global Forecast to 2021

The non-invasive prenatal testing (NIPT) market is expected to reach USD 2.88 billion by 2021 from USD 1.35 billion in 2016 at a CAGR of 16.4% during the forecast period.

Bioinformatics Market

 Bioinformatics Market by Product & Service (Knowledge Management Tools, Data Analysis Platforms (Structural & Functional), Services), Applications (Genomics, Proteomics & Metabolomics), & Sectors (Medical, Academics, Agriculture) - Global Forecast to 2023

The global bioinformatics market is projected to reach USD 13.50 billion in 2023 from USD 6.17 billion in 2017, at CAGR of 14.5%. The base year considered for the study is 2017, and the forecast for the market size is provided for the period between 2018 and 2023.

seeking biotech alpha - 2018 intel

 Hepatitis C Increases Diabetes Risk in Kidney Transplant Recipients

OCTOBER 22, 2018Jared Kaltwasser 

 Click here to sign up for more MD Magazine content and updates. 

 Alzheimer’s can occur in 30s & 40s: Common signs include repeating questions, becoming suspicious of others

ET CONTRIBUTORS|Oct 23, 2018, 03.00 PM IST

Read more at:
//economictimes.indiatimes.com/articleshow/66326477.cms?u

 By Dr Kalyani Karkare 

 Not enough exercise as bad as smoking, diabetes, high blood pressure, Cleveland Clinic study says

Updated Oct 22, 4:07 PM; Posted Oct 22, 11:16 AM 

 

By Julie Washington, The Plain Dealer

jwashington@plaind.com

CLEVELAND, Ohio 

 IN THE JOURNALS PLUS 

Diabetes prevalence reaches 9.7% of U.S. population in 2016 and 2017

October 22, 2018

An estimated 8.5% of the U.S. adult population was diagnosed with type 2 diabetes and 0.5% was diagnosed with type 1 diabetes in 2016 and 2017, according to a study published in BMJ.

In addition, adults with type 2 diabetes made up 91.2% of the U.S. population with some form of diabetes, whereas 5.6% of the population with diabetes had type 1.


 

  1. Healio
  2. Endocrinology
  3. Diabetes

 Even more evidence finds link between herpes virus and Alzheimer’s 

 By 

 Diabetes type 2 - the 50p ‘superfood’ you should add to your daily diet

 

By MATT ATHERTON

PUBLISHED: 07:51, Mon, Oct 22, 2018 | UPDATED: 07:58, Mon, Oct 22, 2018

©2018 BlackRock, Inc. All Rights Reserved.

Sep 25, 2018 By Bob Miller, Rick Rieder

 An exceptionally strong labor market and reasonably firm inflation
have the Fed monitoring the heat in the U.S. economy. 


  September 2018 - 

BlackRock Investment Institute 

We see a growing disconnect between waning market attention to our top 10 geopolitical risks and the likelihood of some of them escalating. Our global BlackRock Geopolitical Risk Indicator (BGRI) has declined since our last update, suggesting the market’s attention to geopolitical risks overall has edged down. Yet the overall reading masks considerable dispersion, and we have raised the likelihood of three of our risks.Global trade tensions is our focus risk this month as U.S. trade disputes with major trading partners carry on. 

 Sep 19, 2018 -  By Russ Koesterich 

 At $3.5 trillion per year, total healthcare spending (public and private) makes up roughly 20% of the U.S. economy. The nation’s 80 million baby boomers provide a stable source of ongoing revenue growth for healthcare companies throughout the value chain. Demographic tailwinds are widely expected to continue to propel this secular story in the United States. 

 Sep 14, 2018 By Michael Fredericks

 In the United States, we continue to observe above-trend fundamental data, including strong corporate earnings, capital expenditures (business investment) and consumer sentiment. U.S. stocks notably outperformed international markets, with the S&P 500 Index rallying over 3% in August whereas European equities, for instance, were negative. We believe U.S. outperformance will likely persist in the near-term, underscoring our preference for more domestic-oriented assets. 

 Oct 1, 2018

By BlackRock Investment Institute

 We see the steady global expansion rolling on, underpinned by above-trend U.S. growth. Yet the range of potential economic outcomes is widening. Gradual increases in U.S. rates are tightening financial conditions globally, and have contributed to bouts of volatility and sharply depreciating emerging market (EM) currencies. We also take a deep dive into the prospects for EMs after an unexpectedly drawn-out selloff. 

 Oct 8, 2018 By Richard Turnill

 Global equities’ nearly decade-long bull run is stoking anxiety about its ability to power on. One concern: narrow breadth — a fragile state when a small group of stocks is contributing the lion’s share of market returns, buoying the broader index. We see today’s strong equity performance, especially in the U.S., as broad-based and driven by healthy fundamentals and solid earnings momentum. 

© 2018 Grand View Research, Inc. All rights reserved.

 Posted On Sep, 05, 2018

Cancer Biomarkers Market: Increasing demand for rapid and specific cancer diagnosis

 

Posted On Sep, 05, 2018 

Regenerative Medicine: Presence of strong product pipeline coupled with emerging applications in gene therapy projected to drive market


Posted On Sep, 05, 2018

 Biosimilars - A Pioneering Approach To Futuristic Treatments!


   June 2018 

The global genomics market size is expected to reach USD 27.6 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 9.7% during the forecast period.

 Published Date: Sep, 2018

Metagenomics Market Size, Share & Trends Analysis Report By Product (Sequencing & Data Analytics), By Technology (Sequencing, Function), By Application (Environmental), And Segment Forecasts, 2018 - 2025

Some of the prominent players operating in this market are Illumina, Inc.; Promega Corporation; Novogene Corporation; Oxford Gene Technology, Inc.; Thermo Fisher Scientific, Inc.; TAKARA BIO INC.; Danaher; QIAGEN; and ELITechGroup. 

seeking biotech alpha - 2018 intel

 Washington, D.C. (September 11, 2018) 

 Small Business Optimism Shatters Record Previously Set 35 Years Ago

 The NFIB Small Business Optimism Indexsoared to 108.8 in August, a new record in the survey’s 45-year history, topping the July 1983 highwater mark of 108. The record-breaking figure is driven by small business owners executing on the plans they’ve put in place due to dramatic changes in the nation’s economic policy. 

 Every cancer, like every patient, is different. Genomic tumor assessments help identify the DNA alterations that are driving the growth of a particular tumor. As we understand more about these gene mutations, we are better able to provide cancer treatment therapies that specifically target changes in the tumor's genomic profile. Information about genomic changes that are unique to your individual cancer may help us determine treatments that may be appropriate for you. It's the promise of precision cancer treatment—a focus on the individual tumor in the individual patient. 

 

Brian Feroldi
(TMFTypeoh)

Feb 23, 2018 at 12:29PM 

Top DNA Stocks to Consider Buying

 Thanks to tremendous advancements in genomic sequencing and the development of gene editing techniques like zinc-finger nuclease and CRISPR (clustered regularly interspaced short palindromic repeats), scientists now have the tools and know-how to make changes to our genetic code like never before. 

 Cancer Genomics

Transforming how we study, diagnose, and treat cancer

April 9, 2018

 

Preliminary Results for September 2018 

Consumer sentiment posted a robust rise in early September, reaching 100.8, the second highest level since 2004-only behind the March 2018 reading of 101.4. 

   

The NFIB Small Business Optimism Index continued its historic 23-month positive trend, with a reading of 107.9 in September, the third highest reading in the survey’s 45-year history. In the small business half of the economy, 2018 has produced 45-year record high measures of job openings, hiring plans, actual job creation, compensation increases (actual and planned), profit growth, and inventory investment. 

The NFIB Research Foundation has collected Small Business Economic Trends data with quarterly surveys since the 4th quarter of 1973 and monthly surveys since 1986. Survey respondents are drawn from NFIB’s membership. The report is released on the second Tuesday of each month. This survey was conducted in September 2018